Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma to Participate in April Investor Conferences

GlobeNewswire April 3, 2025

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 27, 2025

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

GlobeNewswire March 26, 2025

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

GlobeNewswire March 13, 2025

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

GlobeNewswire March 12, 2025

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis

GlobeNewswire March 6, 2025

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

GlobeNewswire March 4, 2025

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

GlobeNewswire February 24, 2025

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

GlobeNewswire January 29, 2025

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 17, 2024

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

GlobeNewswire December 12, 2024

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis

GlobeNewswire December 10, 2024

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

GlobeNewswire December 9, 2024

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

GlobeNewswire November 15, 2024

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

GlobeNewswire November 7, 2024

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire October 31, 2024

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Newsfile October 14, 2024

aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

GlobeNewswire October 8, 2024

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

GlobeNewswire October 2, 2024

aTyr Pharma to Participate in September Investor Conferences

GlobeNewswire August 21, 2024